| Patient | Duke Kahanamoku |
|---|---|
| Date of birth | 1959-08-24 |
| Identifiers | MRN HR-ML050-SYN; SSN (made up) 000-50-6847 |
| Document date | 2026-11-01 |
| Author | Kawika Lindgren-Morrison, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing care for six weeks of breathlessness, ankle swelling and tiredness five years after a heart attack: examination, ECG, chest X-ray, NT-proBNP and laboratory tests, a diuretic, and the plan for an echocardiogram. Concerns: He wants to get back in the ocean, to swim and surf again; He wants to keep working as sheriff; He wants his ʻohana involved as he chooses and his own ways of healing respected. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-16 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Metoprolol tartrate 25 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Furosemide 40 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-03-16 to 2026-04-27 | completed | S |
| Furosemide 20 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-04-27 | active | S |
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril | One tablet twice daily | Oral route | 2026-03-30 to 2026-09-28 | completed | S |
| Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2026-09-28 | active | S |
| Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate | One tablet twice daily with food | Oral route | 2026-03-30 to 2026-04-13 | completed | S |
| Carvedilol 6.25 mg oral tablet, one tablet twice daily with food | One tablet twice daily with food | Oral route | 2026-04-13 to 2026-04-27 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet twice daily with food | One tablet twice daily with food | Oral route | 2026-04-27 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 2026-03-30 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily | One-half tablet daily | Oral route | 2026-04-13 | active | S |
| Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart | Two infusions two weeks apart | Intravenous route | 2026-03-30 to 2026-04-13 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram: sinus rhythm at 92 per minute, Q waves in V1 to V4 from an old anterior infarction, QRS 104 ms, no left bundle branch block, no atrial fibrillation | 2026-03-16 to 2026-03-16 | completed | S |
| Chest X-ray, two views: enlarged heart, upper-lobe venous diversion and small pleural effusions on both sides; no pneumonia | 2026-03-16 to 2026-03-16 | completed | S |
| Transthoracic echocardiography: ejection fraction 30% by biplane method, thinned and akinetic anterior wall and apex, no left ventricular thrombus, dilated left ventricle (end-diastolic diameter 62 mm), moderate functional mitral regurgitation, normal right ventricle, estimated pulmonary artery systolic pressure 42 mmHg | 2026-03-30 to 2026-03-30 | completed | S |
| Invasive coronary angiography by the radial route: chronic total occlusion of the proximal left anterior descending artery filling faintly by collaterals from the right coronary artery, 40% narrowing of the mid right coronary artery and 30% of the circumflex; no lesion suitable for or likely to benefit from revascularization, given the thinned, scarred anterior wall | 2026-04-06 to 2026-04-06 | completed | S |
| Twelve-lead electrocardiogram at the sick visit: sinus rhythm at 96 per minute, old anterior Q waves unchanged, no peaked T waves, no change in QRS width | 2026-04-22 to 2026-04-22 | completed | S |
| Outpatient cardiac rehabilitation for heart failure: 36 sessions over twelve weeks, with supervised pool swimming in the last month and an ocean-safety plan; all sessions completed | 2026-05-26 to 2026-08-14 | completed | S |
| Advance care planning conversation, about 25 minutes, with his consent | 2026-09-14 to 2026-09-14 | completed | S |
| Transthoracic echocardiography after more than 90 days of therapy: ejection fraction 38% by biplane method, anterior wall and apex still thinned and akinetic, left ventricular end-diastolic diameter 58 mm (from 62), mild mitral regurgitation (from moderate), no thrombus, estimated pulmonary artery systolic pressure 30 mmHg | 2026-09-28 to 2026-09-28 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-03-30 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-09-14 | High-dose influenza vaccine, this season | completed | S |
| 2026-09-14 | Respiratory syncytial virus vaccine, single dose | completed | S |
| 2026-09-14 | COVID-19 vaccine, mRNA, this season | completed | S |
| 2026-09-28 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-09-28 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1952 | Heart attack in 1952, at about 61, one of several in his later years; details of its treatment are not recorded in the sources read | D (CLM-0009) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He wants to get back in the ocean, to swim and surf again | active | S |
| He wants to keep working as sheriff | active | S |
| He wants his ʻohana involved as he chooses and his own ways of healing respected | active | S |
Most recent measures: Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 620 on 2026-09-28; Sodium [Moles/volume] in Serum or Plasma 138 on 2026-09-28; Potassium [Moles/volume] in Serum or Plasma 4.6 on 2026-09-28; Creatinine [Mass/volume] in Serum or Plasma 1.14 on 2026-09-28; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 70 on 2026-09-28; Glucose [Mass/volume] in Serum or Plasma 95 on 2026-09-28; Magnesium [Mass/volume] in Serum or Plasma 2 on 2026-09-28; Hemoglobin [Mass/volume] in Blood 14.1 on 2026-09-28; Ferritin [Mass/volume] in Serum or Plasma 248 on 2026-09-28; Iron saturation [Mass Fraction] in Serum or Plasma 27 on 2026-09-28; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-03-16; Hemoglobin A1c/Hemoglobin.total in Blood 5.9 on 2026-03-16; Cholesterol [Mass/volume] in Serum or Plasma 130 on 2026-04-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 62 on 2026-04-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 45 on 2026-04-27; Triglyceride [Mass/volume] in Serum or Plasma 115 on 2026-04-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 2026-04-27; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-14; Overall summary score [KCCQ-12] 80 on 2026-09-28; Left ventricular Ejection fraction 38 on 2026-09-28; Total score [Mini-Cog] 5 on 2026-09-14; Total score [AUDIT-C] 0 on 2026-09-14 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction. |
| Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952 | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history. |
| Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime. |
| Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%) | active | confirmed | E61.1 | S — Synthetic finding at the heart failure workup. |
| Viral gastroenteritis for two days, with volume depletion, potassium 5.5 mmol/L and a rise in creatinine on sacubitril-valsartan, spironolactone, empagliflozin and furosemide; settled with sick-day rules | resolved | confirmed | A08.4 | S — Synthetic intercurrent problem at an unscheduled visit; it follows from his heart failure medicines and does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-16 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 2450 | pg/mL | Below 125 pg/mL makes heart failure unlikely outside the hospital | High | S |
| 2026-03-16 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-16 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-16 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 81 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-16 | Glucose [Mass/volume] in Serum or Plasma | 102 | mg/dL | 70-99 mg/dL | High | S |
| 2026-03-16 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-03-16 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-03-16 | Ferritin [Mass/volume] in Serum or Plasma | 62 | ng/mL | In heart failure, below 100 ng/mL, or 100 to 299 with transferrin saturation below 20%, is iron deficiency | Low | S |
| 2026-03-16 | Iron saturation [Mass Fraction] in Serum or Plasma | 16 | % | 20-50% | Low | S |
| 2026-03-16 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-03-16 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | <=5.6% | High | S |
| 2026-03-16 | Cholesterol [Mass/volume] in Serum or Plasma | 168 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-03-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 92 | mg/dL | Secondary-prevention goal below 70 mg/dL | High | S |
| 2026-03-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-03-16 | Triglyceride [Mass/volume] in Serum or Plasma | 160 | mg/dL | <=149 mg/dL | High | S |
| 2026-03-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-55 U/L | Normal | S |
| 2026-03-16 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-03-16 | Overall summary score [KCCQ-12] | 38 | {score} | S | ||
| 2026-03-30 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-30 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 76 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-30 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-30 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-03-30 | Left ventricular Ejection fraction | 30 | % | 50-70% | Low | S |
| 2026-04-13 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 69 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-13 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-13 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-04-13 | Overall summary score [KCCQ-12] | 56 | {score} | S | ||
| 2026-04-22 | Sodium [Moles/volume] in Serum or Plasma | 133 | mmol/L | 135-145 mmol/L | Low | S |
| 2026-04-22 | Potassium [Moles/volume] in Serum or Plasma | 5.5 | mmol/L | 3.5-5.1 mmol/L | High | S |
| 2026-04-22 | Creatinine [Mass/volume] in Serum or Plasma | 1.52 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-04-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 50 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-04-22 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-22 | Magnesium [Mass/volume] in Serum or Plasma | 2.1 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-04-27 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-27 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.2 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-27 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-27 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-04-27 | Cholesterol [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 62 | mg/dL | Secondary-prevention goal below 70 mg/dL | Normal | S |
| 2026-04-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 45 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-04-27 | Triglyceride [Mass/volume] in Serum or Plasma | 115 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 2026-04-27 | Overall summary score [KCCQ-12] | 66 | {score} | S | ||
| 2026-09-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-28 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 620 | pg/mL | Below 125 pg/mL makes heart failure unlikely outside the hospital | High | S |
| 2026-09-28 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.14 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 70 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-28 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-28 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-09-28 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-09-28 | Ferritin [Mass/volume] in Serum or Plasma | 248 | ng/mL | In heart failure, below 100 ng/mL, or 100 to 299 with transferrin saturation below 20%, is iron deficiency | Normal | S |
| 2026-09-28 | Iron saturation [Mass Fraction] in Serum or Plasma | 27 | % | 20-50% | Normal | S |
| 2026-09-28 | Left ventricular Ejection fraction | 38 | % | 50-70% | Low | S |
| 2026-09-28 | Overall summary score [KCCQ-12] | 80 | {score} | S | ||
| 2026-09-14 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-09-14 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-16 | Body height | 185 | cm | S |
| 2026-03-16 | Body weight | 97.6 | kg | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 28.5 | kg/m2 | S |
| 2026-03-16 | Systolic blood pressure | 142 | mm[Hg] | S |
| 2026-03-16 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-03-16 | Heart rate | 92 | /min | S |
| 2026-03-16 | Respiratory rate | 20 | /min | S |
| 2026-03-16 | Body temperature | 36.7 | Cel | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| 2026-03-30 | Body height | 185 | cm | S |
| 2026-03-30 | Body weight | 95 | kg | S |
| 2026-03-30 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 2026-03-30 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-03-30 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-03-30 | Heart rate | 86 | /min | S |
| 2026-03-30 | Respiratory rate | 18 | /min | S |
| 2026-03-30 | Body temperature | 36.6 | Cel | S |
| 2026-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 2026-04-13 | Body height | 185 | cm | S |
| 2026-04-13 | Body weight | 93.6 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 27.3 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 74 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 36.6 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-04-27 | Body height | 185 | cm | S |
| 2026-04-27 | Body weight | 93 | kg | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 27.2 | kg/m2 | S |
| 2026-04-27 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-04-27 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-04-27 | Heart rate | 68 | /min | S |
| 2026-04-27 | Respiratory rate | 16 | /min | S |
| 2026-04-27 | Body temperature | 36.6 | Cel | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-28 | Body height | 185 | cm | S |
| 2026-09-28 | Body weight | 92.8 | kg | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 27.1 | kg/m2 | S |
| 2026-09-28 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-09-28 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-09-28 | Heart rate | 64 | /min | S |
| 2026-09-28 | Respiratory rate | 16 | /min | S |
| 2026-09-28 | Body temperature | 36.5 | Cel | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-22 | Body height | 185 | cm | S |
| 2026-04-22 | Body weight | 91.4 | kg | S |
| 2026-04-22 | Body mass index (BMI) [Ratio] | 26.7 | kg/m2 | S |
| 2026-04-22 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-04-22 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-04-22 | Heart rate | 96 | /min | S |
| 2026-04-22 | Respiratory rate | 16 | /min | S |
| 2026-04-22 | Body temperature | 37.6 | Cel | S |
| 2026-04-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-14 | Body height | 185 | cm | S |
| 2026-09-14 | Body weight | 92.6 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 27.1 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 64 | /min | S |
| 2026-09-14 | Respiratory rate | 16 | /min | S |
| 2026-09-14 | Body temperature | 36.6 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-16 | Establishing care for six weeks of breathlessness, ankle swelling and tiredness five years after a heart attack: examination, ECG, chest X-ray, NT-proBNP and laboratory tests, a diuretic, and the plan for an echocardiogram | finished | S |
| 2026-03-30 | Two-week review: echocardiogram, heart failure cardiology consultation the same day, the diagnosis, and guideline-directed medicines | finished | S |
| 2026-04-13 | Two-week review after sacubitril-valsartan, carvedilol and empagliflozin: kidney function, potassium, angiography result and the next medicine | finished | S |
| 2026-04-27 | Two-week review, five days after the sick visit: kidney function and potassium, medicine doses, lipids, and cardiac rehabilitation adapted to the ocean | finished | S |
| 2026-09-28 | Six-month review: repeat echocardiogram after more than 90 days of therapy, the defibrillator decision, iron, the delayed titration step, and plans for the year | finished | S |
| 2026-04-22 | Same-day sick visit for vomiting and diarrhea on heart failure medicines | finished | S |
| 2026-09-14 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Culturally safe care: address him as Mr. Kahanamoku, as he asked; take time; explain each test and medicine plainly; involve his ʻohana as he chooses while he makes the decisions | completed | GL-KEOLAMAMO, GL-NH-HF-2015 | S |
| Heart failure cardiology consultation on the day of the two-week visit, with an echocardiogram, to confirm the diagnosis and its cause and to plan guideline-directed medical therapy, ischemic evaluation and device decisions | completed | GL-HF-2022, GL-HFREF-ECDP-2024, GL-CMID-2026 | S |
| Furosemide 40 mg every morning for congestion, with a daily weight and a written plan; metabolic panel and magnesium in one to two weeks; lower the dose when he is dry | completed | GL-HF-2022, GL-CMID-2026 | S |
| Baseline tests: ECG, chest X-ray, NT-proBNP, metabolic panel and magnesium, blood count, iron studies, TSH, hemoglobin A1c, lipids and ALT; echocardiogram at the two-week visit | completed | GL-HF-2022, GL-CMID-2026 | S |
| Atorvastatin raised from 40 to 80 mg for LDL 92 mg/dL; lipid panel in four to twelve weeks; goal below 70 mg/dL | completed | GL-CCD-2023, GL-CMID-2026 | S |
| Sodium: less salted and dried fish, shoyu and salty party food, using the foods he already eats; no routine fluid restriction; daily weights | completed | GL-HF-2022 | S |
| Vaccinations: pneumococcal, influenza, COVID-19 and RSV as due, because heart disease raises the risk of severe respiratory infection | completed | GL-HF-2022, GL-CDC-IMZ-2026 | S |
| Native Hawaiian healing alongside clinic care, if he wishes: lomilomi through Ke Ola Mamo, a Native Hawaiian Health Care System; he will tell the clinic before using any plant medicine so that interactions can be checked; the clinic asks nothing further about his practices | completed | GL-KEOLAMAMO | S |
| Guideline-directed medical therapy: stop lisinopril and start sacubitril-valsartan 24/26 mg twice daily 36 hours after the last dose; change metoprolol tartrate to carvedilol 3.125 mg twice daily; empagliflozin 10 mg daily; add spironolactone when potassium and kidney function allow; raise one medicine every two weeks toward target doses, with a metabolic panel one to two weeks after each change | completed | GL-HF-2022, GL-HFREF-ECDP-2024, GL-CMID-2026 | S |
| Intravenous ferric carboxymaltose 750 mg at the two-week visit and again two weeks later, for iron deficiency in heart failure with reduced ejection fraction; iron studies again at about six months | completed | GL-HF-2022, GL-CMID-2026 | S |
| Invasive coronary angiography within two weeks to define the coronary disease and whether revascularization could help | completed | GL-HF-2022, GL-CCD-2023 | S |
| Defibrillator decision: repeat echocardiogram after at least 90 days of optimized therapy; a primary-prevention ICD if the ejection fraction stays at 35% or below with NYHA class II to III | completed | GL-HF-2022, GL-VA-ICD-2017, GL-CMID-2026 | S |
| Sick-day rules: on days of vomiting, diarrhea or not drinking, hold empagliflozin, furosemide, spironolactone and sacubitril-valsartan, keep carvedilol if blood pressure allows, drink small amounts often, and restart when eating and drinking normally for a day; a written card | completed | GL-HF-2022, GL-HFREF-ECDP-2024 | S |
| Cardiac rehabilitation for heart failure, 36 sessions, adapted to an ocean athlete: pool swimming in the program, then calm water inside the reef with a companion and near a lifeguard, no breath-hold diving, no big surf until cleared, water through the morning, and out of the water at once for chest pain, lightheadedness or unusual breathlessness | completed | GL-HF-2022, GL-CMID-2026 | S |
| Laboratory tests drawn at the clinic on the day of each medicine change or by the clinic's nurse at home, with nurse calls to titrate doses between visits | completed | GL-HFREF-ECDP-2024, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Euvolemia: no ankle swelling or orthopnea, with a steady dry weight | 2026-04-27 | completed | Dry weight about 93 kg; no edema or orthopnea; furosemide reduced to 20 mg | S |
| All four guideline-directed medicines at the highest doses he tolerates within three months | 2026-09-28 | active | All four classes started within two weeks of diagnosis; carvedilol 12.5 mg twice daily, empagliflozin and spironolactone at their doses; sacubitril-valsartan stayed at the starting dose for five months after a missed titration step and was raised at six months | S |
| KCCQ-12 at least 20 points higher and NYHA class I to II within six months | 2026-09-28 | completed | KCCQ-12 38 to 80; NYHA class I to II | S |
| Back in the ocean safely, swimming in calm water with a companion | 2026-09-28 | completed | Swimming three mornings a week in calm water inside the reef with a friend, after cardiac rehabilitation | S |
| LDL cholesterol below 70 mg/dL | 2026-04-27 | completed | LDL 62 mg/dL on atorvastatin 80 mg | S |